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Cytokines are a group of small proteins involved in the regulation of infection, immune responses and inflam-
mation. Since altered cytokine responsiveness has been linked to Oral Squamous Cell Carcinoma (OSCC), research 
to date indicates the possibility of using salivary pro- and anti-inflammatory proteins for screening of oral disorders. 
OSCC is a multistep neoplasia in which many genetic and epigenetic changes have been correlated to cancerous 
transformation of oral potentially malignant disorders (OPMD) such as oral leukoplakia, erythroplakia and lichen 
planus. The goal of the innovative salivary diagnostics is the identification of a single or multiple biomarkers that 
will serve as a clinical test facilitating the diagnosis of patients predisposed to develop OSCC. Based on scientific 
literature review, this article summarizes the results from nine articles, all of them being case-control studies where 
TNF-α, IL-1β, IL-6 and IL-8 were considered possible indicators of malignant transformation.




OSCC represents the most common malignant neoplasm 
of the oral cavity and it comprises 80-90% of Head and 
Neck Cancers (HNC). Over the past two decades, the 
5-year survival rate remains at about 50% due to its 
initially asymptomatic nature, leading to advanced sta-
ges diagnosis with few therapeutic options. Besides, its 
tendency to produce regional metastases in the neck, as 
well as its frequent recurrences after treatments should 
be taken into account. OSCC tumors appear through a 
series of molecular mutations leading to uncontrolled 
cellular growth from hyperplasia areas to dysplastic le-
sions, to carcinoma in situ and is finally followed by in-
vasive carcinoma. Smoking and drinking alcohol along 
with environmental and genetic factors are considered 
major risk factors in the western world, whereas in Asian 
countries tobacco/areca nut/betel leaf chewing has an 
important role in the aetiology. Human papillomavirus 
(HPV) infections have also been reported in those pa-
tients but with scarce influence on OSCC located in the 
anterior part of the mouth (1). Currently, the diagnosis 
is based on a histopathologic examination of the lesion 
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from an excisional biopsy taken from the suspected area 
upon direct visual clinical checkup (2). The primary 
treatment for early stages is a surgical intervention. Ra-
dio/chemotherapy is indicated when there are affected 
margins after the surgical resection or the presence of 
metastatic lesions observed in more advanced disease 
cases. Therefore, early detection is crucial for improving 
the treatment outcomes and  the survival rate of the pa-
tients. Oral cancer develops through a multistep process 
whose mechanism of action remains not well unders-
tood, but the initial presence of a precursor cell subse-
quently evolving into cancer has been established (3). 
A complex of genetic, epigenetic and metabolic chan-
ges have been correlated to cancerous transformation 
of Oral Potentially Malignant Disorders (OPMD) (4). 
According to the World Health Organization (WHO), 
lesions and conditions of the oral mucosa, with a predis-
position to malignant conversion, are defined as OPMD. 
Typical representatives are oral leukoplakia, erythropla-
kia, lichen planus and submucous fibrosis. Determining 
which OPMD will follow a stable clinical course and 
which will progress to invasive carcinoma is challen-
ging with the routine histopathological diagnosis and 
has limited prognostic value. Therefore, the develop-
ment of alternative methods for predicting malefic po-
tential of suspicious lesions is of high demand. Although 
several different biological and molecular factors have 
been proposed as diagnostic tools for oral cancer, there 
is a long way to go until a real impact on routine clinical 
care is established. Proteomic and transcriptomic indi-
cators have yielded promising results while information 
obtained from microorganisms and immunologic factors 
remain one of the more intriguing aspects in the pursuit 
of biomarkers, identified from various body fluids (5). 
The interest in human saliva has evidently increased due 
to its advantages, in some cases, over other samples such 
as blood, urine and exfoliated cells. Saliva comprises a 
non-invasive, rapid to collect, cost-effective and easy 
to store biomaterial (6). The array of salivary molecu-
lar and microbial analytes (proteins, enzymes, DNA, 
mRNA, etc.) makes it a significant source of discrimi-
natory, measureable and quantifiable parameters (8-10), 
such as pro- and anti-inflammatory proteins (cytokines) 
whose expressions are regulated by the coordinated ac-
tivation of various signaling pathways as a response to 
inflammation. An increasing number of investigations 
report the use of salivary cytokines as diagnostic tool 
for oral disorders. Recent research has suggested that 
nuclear factor - κB (NF- κB) dependent cytokine levels 
are elevated in saliva and tissue specimens of patients 
with OPMD (9). Thus, cytokines with proinflammatory 
and proangiogenic activity are thought to be prominent 
agents in the local and systemic nature of these respon-
ses, and a promising tool that could indicate early cancer 
onset. However, more extensive studies with a larger 
sample population and sensitivity and specificity of the 
clinical targets are required to validate prognostic signi-
ficance.
The main aim of this article is to review the available 
literature and to summarize the implications of salivary 
inflammatory proteins for studying OPMD, as well as to 




A bibliographical search was performed on Pubmed, 
where scientific articles were chosen based on keywords: 
“salivary interleukins, oral premalignant disorders, oral 
potentially malignant disorders, oral precancer”. 
The inclusion criteria for selecting the articles were:
1. The articles reported research into interleukins in hu-
man saliva samples.
2. The methodology of detection and quantification of 
salivary interleukins was described and validated.
3. The samples were obtained from individuals with 
OPMD including Oral leukoplakia, Proliferative verru-
cous leukoplakia and Oral lichen planus.
4. The articles reported detailed results on the interleu-
kins findings, their role in the diagnosis, and their rela-
tionship with possible malignant degeneration.
5. All the articles were published in English over the pe-
riod of the last 15 years.
Finally, nine publications that fulfilled the inclusion cri-
teria were selected and the mean of analyzed variables, 
such as the investigated inflammatory factors and their 
importance or role in the diagnosis of malignant trans-
formation, was reported based on descriptive statistical 
analysis only.
Results
- Data on the selected articles
All the articles selected for this review were case-control 
studies, with the oldest dating from 2004 and the most 
recent from 2016. The publications come from six diffe-
rent countries, namely Croatia, Belgium, Austria, Spain, 
Japan and India (Table 1). Saliva samples had been ob-
tained from voluntary study participants − healthy in-
dividuals (Controls) and patients, clinically diagnosed 
with OPMD – who had signed a written consent form 
approved by the Institutional Ethical Committee of the 
respective university hospital departments. For compari-
son and validation of statistical differences between the 
groups, mainly non-parametric Man-Whitney test for 
independent samples was performed.
- Data on findings regarding the implication of cytokines 
for studying OPMD
As inflammation has previously been linked to the pa-
thogenesis of OSCC, multiple reports suggest that Nu-
clear Factor κB (NF-κB)-dependent overproduction of 
certain cytokines is similarly observed in patients with 
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OPMD. As the most typical representative,  homoge-
neous leukoplakia has been widely explored and seve-
ral authors have published case-control studies where 
Enzyme Linked Immunoadsorbent Assay (ELISA) 
was used to detect and quantify inflammatory proteins 
in biofluid samples. Patients with clinically confirmed 
oral leukoplakia were registered to have significantly hi-
gher salivary concentration of Interleukin 6 (IL-6) when 
compared to healthy individuals (12-14). Besides, Tu-
mor Necrosis Factor alpha (TNF-α) and IL-8 levels were 
also found elevated in the leukoplakia samples (13,14). 
In contrast, in 2012, Brailo et al. (14) found considera-
bly lower values of salivary IL-1β compared to controls 
and no differences in IL-6 and TNF-α levels between 
the same groups. It should be considered that the OPMD 
group was composed of patients diagnosed with oral 
leukoplakia without epithelial dysplasia, as well as with 





S. Pezelj-Ribaric and I. 
B. Prso
(2004)
40 Oral Lichen Planus (OLP) ELISA saliva Considerably higher TNF-α levels 
were elevated in the pathology in 
comparison with the control cases.
N. L. Rhodus (2005) 13 OSCC & OLP ELISA saliva Significantly increased IL-6 concen-
tration in PVL cases compared to 
healthy individuals
Y. Zhang et al.
(2008)
30 Oral lichen planus 
(OLP)
ELISA saliva IL-6, IL-8 and TNF-α  concentra-
tions were increased in OLP pa-
tients in comparison with healthy 
volunteers.
M.Sharma et al. (2011) 20 Oral leukoplakia & peri-
odontitis
ELISA  saliva IL-6 higher in leukoplakia with co-
existing periodontitis than in con-
trols. IL-6 level was found to be in-
creased with increase in the severity 
of dysplasia. 
V. Brailo et al. (2012) 28,29 OSCC & Oral leukoplakia ELISA saliva Patients with oral leukoplakia had 
notably lower IL-1β  and no signiffi-
cant differences in IL-6 values com-
pared to controls. No considerable 
differences in TNF-α levels were 
found between the groups. 
R.Cerovic (2013) 19 OSCC & Oral lichen pla-
nus (OLP) 
ELISA  saliva TNF-α and IL-6 values were found 
significantly higher in OSCC and 
OLP samples.
J. Kaur (2015) 50, 54, 51 Oral leukoplakia, oral 
lichen planus & oral sub-
mucous fibrosis
ELISA  saliva Salivary TNF-α, IL-6, and IL-8 sig-
nificantly increased in oral leukopla-
kia, submucous fibrosis, and OLP in 
contrast to healthy subjects.
L. Bagan  (2016) 20 OSCC & Proliferative 
Verrucous Leukoplakia 
(PVL)
ELISA saliva Significantly increased IL-6 con-
centration in PVL cases compared 
to healthy individuals.
T. Dineshkumar (2016) 50 Oral leukoplakia and Oral 
Submucous Fibrosis 
ELISA saliva IL-6 values higher in Leukoplakia 
than in controls.
Table 1: Data on findings of investigated cytokines in OPMDs.
mild, moderate and severe epithelial dysplasia, based on 
histopathological reports. A single study was conducted 
comparing IL-6 salivary levels in Proliferative verru-
cous leukoplakia (PVL) and control samples. PVL starts 
as simple homogenous leukoplakia but progresses to ve-
rrucous forms with a high risk of malignant transforma-
tion and recurrence after treatment. Notably increased 
values were registered in the pathology samples in con-
trast to the control cases (15). Expression patterns of sa-
livary cytokines were investigated in Oral lichen planus 
(OLP) – a complex local immunologically mediated di-
sease of the oral mucosa. In 2004 a group of authors (16) 
reported elevated secretion of TNF-α in the reticular and 
erosive/atrophic forms of OLP. A year later Rhodus (17) 
published a case-control study with multiple cytokine 
detection. TNF-α, IL-1α, IL-6 and IL-8 were determined 
in human spit by ELISA and found significantly increa-
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sed in patients with clinically confirmed OLP in contrast 
to healthy subjects. In support of these findings are also 
other working groups (13,14,19). The potential  role of 
IL-18 as an indicator for OLP diagnosis was shown by 
Y. Zhang et al (19). Some researchers have reported a 
correlation between target cytokine abundance and cli-
nico-pathologic features such as size and aggressiveness 
of the premalignant lesion (14, 21); a number of arti-
cles also take into account the patients’ smoking habits 
(12,13,15,21).
Discussion
Nomenclature, definitions and classification issues of 
oral precancer were widely discussed in a workshop 
coordinated by the WHO Collaborating Centre for Oral 
Cancer and Precancer in the UK in 2005. The consen-
sus views of an expert group were presented in a report 
reflecting the better understanding of multi-step carcino-
genesis in the oral mucosa (21). According to the report, 
the term ‘potentially malignant disorders’ was recom-
mended to refer to precancer as it conveys that not all 
disorders described under this term may transform into 
cancer. However, since then many other publications 
have analysed the above terms, mainly the definition of 
oral leukoplakia (22). Based on the epidemiologic re-
search, the epithelial lesion could be the cause of most 
oral malignancies. Identification of etiological factors 
and clinical and histopathological methods for diagno-
sis are in increasing need for prevention and early treat-
ment. Oral epithelial dysplasia (OED) is a histopatholo-
gical term used to describe tissue changes observed in 
a chronic, progressive and premalignant disorder of the 
oral mucosa (23). Moreover, dysplastic changes are con-
sistently seen in the mucosa adjacent to the tumor in pa-
tients with invasive OSCC. OED is considered the main 
histologic marker of possible evolution to malignancy 
and is thought to be predictive of an increased rate of de-
velopment of SCC (24). Other techniques for diagnosis 
of OED and possible malignant potential of oral lesions 
have been proposed: brush biopsy, liquid-based cytolo-
gy, toluidine blue, vizilite technique and oral auto fluo-
rescence (25). However, their specificity and sensitivity 
are not as reliable as the incisional biopsy and histologic 
method. Oral leukoplakia is noted as the most common 
premalignant disorder in the oral mucosa with malignant 
transformation rates varying from 1-17% (26-30). The 
variety of manifestation forms and potential to convert 
into SCC has stimulated growing interest in research at 
cellular and molecular levels. A greater risk are conside-
red to be the non-homogenous forms such as verrucous, 
nodular (speckled), and erythroplastic types (31,32). Im-
munological analysis of leukoplakia and OLP specimens 
reported the presence of different inflammatory cells in 
connective tissue, which suggests chronic inflammation 
(25). This ongoing inflammatory response causes pro-
gressive damage to the body leading to different disea-
ses. Salivary analytes have already been proved useful 
for the detection of local, systemic and infectious di-
sorders (33–36). According to the National Institute of 
Health (NIH), a biomarker is an objectively measured 
and evaluated indicator of normal biologic and pathoge-
nic processes or pharmacologic responses to therapeutic 
treatment that exists in a variety of forms including an-
tibodies, microbes, DNA, RNA, lipids, metabolites and 
proteins (34). In terms of biomarkers for inflammatory 
response, there is a rise in expression of cytokines. They 
are secreted from epithelial and immune cells, thereby 
promoting concentration of macrophages and neutro-
phils and thus producing inflammation (35). The clini-
cal significance of salivary cytokines has grown since 
powerful evidence has revealed the critical involve-
ment of NF-κB mechanism of action in carcinogenesis, 
apoptosis protection and chemoresistance in neoplasia 
including breast, ovarian, gastric, pancreatic and HNC 
(39–42). The NF-κB is a key player in inflammatory res-
ponse and its signaling pathway is largely based on its 
role in the expression of proinflammatory agents inclu-
ding cytokines such as IL-1, IL-6, TNF-α, chemokines, 
and adhesion molecules (40). Besides, it has been shown 
that OSCC cells express increased levels of TNF-α, IL-
1α, IL-6 and IL-8 (10,11). The local and systemic nature 
of these responses suggests the hypothesis that altered 
proinflammatory cytokine responsiveness is tightly as-
sociated with precancer and cancer and could contribute 
to the pathogenesis of the oral malignancy.
All of the case-control studies described in this review 
are in support of the hypothesis, demonstrating signifi-
cant growth of IL-1α, IL-6, IL-8 and TNF-α levels in pa-
tients with OPMD when compared to healthy individuals 
(12-21). The higher rates of NF-κB mediators might be 
associated with the development of oral precancerous 
and cancerous lesions. In normal cellular conditions, 
stimulation with cytokines leads to growth inhibition, 
whereas in oral cancer cells up regulation of positive 
cell cycle regulators such as NF-κB and Signal Transdu-
cers and Activations of Transcription (STAT) pathway 
contributes to cell survival and proliferation. Although 
TNF-α causes necrosis of some types of tumors, it might 
act as an inducer of tissue remodeling required for tumor 
growth and spread. IL-6 is a multifunctional cytokine, 
originally described as a regulator of immune and in-
flammatory response signaling but also detected in mul-
tiple epithelial tumors (43). Hence, elevated secretion of 
IL-6, IL-8 and TNF-α in OPMD might be indicative for 
the transition of a lesion from benign into malignant. It 
is suggested that altered cytokine production and res-
ponsiveness in oral cancer takes place primarily in the 
oral cavity (14). Thus, the search for OSCC biomarkers 
in saliva becomes an attractive alternative to other bio-
fluids approach due to its direct contact with the oral mu-
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cosa and lesions. Furthermore, we should highlight that 
IL-1β was reported to have the highest salivary values of 
all studied cytokines in comparison to serum, where the 
values were below the limit of detection (14). It remains 
under discussion whether increased salivary cytokines 
concentration might be a result of a lesion with epithe-
lial discontinuity and surrounding inflammation, not 
related to cancerogenic conditions. For instance, perio-
dontal diseases can enhance the secretion of several in-
terleukins (44). In addition, correlation studies between 
IL-6 levels and histopathological grading demonstrated 
a positive association (11). IL-6 was found to be rising 
from well differentiating to moderate and poorly diffe-
rentiating lesions in serum and saliva. These findings 
suggest this cytokine as a marker that can be associated 
with the severity and aggressiveness of the disease. Va-
rious studies have shown relation of IL-6 with clinical 
staging in OSCC (42-45). Similarly, histological grading 
of OPMD has been proposed to influence the levels of 
salivary cytokines in a growth manner, correlating with 
the level of epithelial dysplasia (10,14).
Conclusions
Cytokines are potential key players in salivary diagnos-
tics approaches and currently under investigation as the-
rapeutic targets or agents. Results from diverse studies 
present evidences that salivary proinflammatory cytokine 
levels differ significantly between healthy individuals and 
patients diagnosed with OPMD and OSCC. Thus, they 
strengthen the potential of these biomolecules to validate 
their prognostic and/or diagnostic utility. Whether cytoki-
ne increase happens before oral cancer becomes clinically 
evident and whether it could be used for monitoring the 
malignant transformation of suspicious lesions needs to 
be further confirmed by larger-scale studies. 
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